Admissions Open: MAD-X for UPSC Prelims 2027 · Batch starts 1st Nov 2026 Explore MAD-X

Lenacapavir HIV Capsid Inhibitor – First Long-Acting HIV Drug

Context

Lenacapavir, the world’s first long-acting HIV capsid inhibitor, confirmed that the HIV capsid is a stable and reliable drug target. (Page 6)

What is Capsid?

(Page 7 diagram shows capsid as a protein shell enclosing viral genetic material.)

Capsid = Protein shell around virus protecting its RNA.

Why Discovery Matters

  1. Capsid is Essential
    If mutated heavily → Virus weakens or dies.
  2. Resistance Slower
    Earlier drugs faced rapid resistance.
    Capsid mutations damage virus → Harder to resist.
  3. New Drug Class
    Opens path for capsid-targeting medicines.
  4. Long-Acting Treatment
    Lenacapavir injection once every six months.

What is HIV?

  • Human Immunodeficiency Virus
  • Attacks CD4 cells (immune system)

Transmission

  • Mother to child (pregnancy/birth/breastfeeding)
  • Infected blood transfusion
  • Sharing needles
  • Unprotected intimate contact
  • Not spread by casual contact
WhatsApp Image 2026 02 25 at 6.00.25 PM
WhatsApp Image 2026 02 25 at 6.00.25 PM 1
PYQ – 2013, Ans – B
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted

Lenacapavir HIV Capsid Inhibitor – First Long-Acting HIV Drug

Got a question? We're here to help!

Our dedicated Student Support team is ready to assist you and guide you every step of the way.
Reach out to us, and let’s tackle your queries together!

Copyright © 2026 USARAMBHA EDUCATION (UnderStand UPSC). All Rights Reserved.

MAD-X Orientation

Talk to Our Counsellor

Share your details and our counselling team will call you back in 10 minutes.

Please enter your name.
+91
Please enter a valid 10-digit mobile number.
When do you plan to enroll in MAD-X?
Please select an option.

Thank you, !

Our counselling team will call you within 10 minutes.
Please keep your phone handy.

0
Would love your thoughts, please comment.x
()
x